Ganaton (itopride) / Abbott 
Welcome,         Profile    Billing    Logout  
 20 Diseases   9 Trials   9 Trials   107 News 


12»
  • ||||||||||  Ganaton (itopride) / Abbott
    Journal:  The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease. (Pubmed Central) -  Apr 4, 2024   
    No adverse effects were noted. The presented study clearly demonstrates that in patients ineffectively treated with PPIs, the addition of itopride to the therapy for 8 weeks without changing the PPI dose, significantly improves the efficacy of treatment of reflux disease and thus shortens the need for medication usage and reduces the costs of therapy, potential side effects of PPI, improves the patient's quality of life and decreases the frequency of medical appointments.
  • ||||||||||  Ganaton (itopride) / Abbott
    PK/PD data, Preclinical, Journal:  Statistically Optimized Polymeric Buccal Films of Eletriptan Hydrobromide and Itopride Hydrochloride: An In Vivo Pharmacokinetic Study. (Pubmed Central) -  Nov 25, 2023   
    The drug was found to rapidly permeate across the buccal mucosa, leading to increased bioavailability of the drug: C of 130 and 119 ng/mL of ITHC and EHBR, respectively, as compared to 96 (ITHC) and 90 ng/mL (EHBR) of oral solution. The conclusion can be drawn that possible reasons for the enhanced bioavailability could be the increased surface area in the form of buccal films, its rapid disintegration, and faster dissolution, which led toward the rapid absorption of the drug into the blood stream.
  • ||||||||||  Cidine (cinitapride) / Almirall, Acofide (acotiamide) / Zeria Pharma, Astellas, Ganaton (itopride) / Abbott
    Clinical, Retrospective data, Review, Journal:  Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis. (Pubmed Central) -  Nov 4, 2023   
    Metoclopramide and cinitapride may have a better efficacy than other prokinetics in the treatment of FD, and cinitapride may have a lower risk of total adverse events. Further studies using uniform definitions or validated tools to measure the total efficacy rate are needed.
  • ||||||||||  Ganaton (itopride) / Abbott
    Journal:  Rational treatment of patients with functional dyspepsia (Pubmed Central) -  Oct 29, 2022   
    Against the background of possible motor disorders, prokinetics are also one of the possible treatment options, but cisapride has long been withdrawn from sale due to cardiotoxicity, the use of domperidone and metoclopramide is limited due to side effects, especially with long-term therapy, so currently the only prokinetic that can be used in everyday clinical practice is itopride. In refractory cases, tricyclic antidepressants and psychotherapeutic approaches are another effective treatment option.
  • ||||||||||  Ganaton (itopride) / Abbott
    Journal:  Development of Novel Unfolding Film System of Itopride Hydrochloride Using Box-Behnken Design-A Gastro Retentive Approach. (Pubmed Central) -  Aug 27, 2022   
    The pharmacokinetic study revealed greater AUC (area under the curve) and long half-life with the designed O-IH-UF formulation, confirming that the unfolding film type can be a favorable drug system for enhancing the bioavailability of low soluble drugs. The results showed that unfolding types of gastro retentive systems could potentiate the drugs with stability issues in an alkaline medium or those with absorption in acidic conditions.
  • ||||||||||  Ganaton (itopride) / Abbott
    DEFINING A THRESHOLD OF SEVERE FUNCTIONAL DYSPEPSIA FOR USE IN A CLINICAL SETTING (Science Lounge) -  Jul 20, 2022 - Abstract #UEGW2022UEGW_2249;    
    Symptomatically severe functional dyspepsia can be defined by scores on either of two validated measures, the NDI and LPDS. Thresholds defined for both instruments have been demonstrated to correspond to symptomatically severe disease and with impact on other aspects of patient wellbeing.
  • ||||||||||  tamoxifen / Generic mfg., midazolam hydrochloride / Generic mfg.
    Journal:  Different substrate elimination rates of model drugs pH-dependently mediated by flavin-containing monooxygenases and cytochromes P450 in human liver microsomes. (Pubmed Central) -  Jan 14, 2022   
    In contrast, the metabolic clearance of control drug midazolam at pH 8.4 was half that at pH 7.4. The ratios of clearance values at pH 8.4 to those at pH 7.4 and the substrate pKa (base) values of reported metabolic N-oxygenation sites of trimethylamine, benzydamine, clomipramine, chlorpromazine, tamoxifen, itopride, loxapine, xanomeline, tozasertib, dasatinib, and clozapine were significantly correlated (r = 0.60, p  8.4, could prove useful for predicting the contributions of FMO3 to N-oxygenations as part of drug development.
  • ||||||||||  tozasertib (MK-0457) / Merck (MSD), Ganaton (itopride) / Abbott
    Journal:  Predicted Contributions of Flavin-containing Monooxygenases to the NOxygenation of Drug Candidates Based on their Estimated Base Dissociation Constants. (Pubmed Central) -  Dec 29, 2021   
    The ratios of clearance values at pH 8.4 to those at pH 7.4 and the substrate pKa (base) values of reported metabolic N-oxygenation sites of trimethylamine, benzydamine, clomipramine, chlorpromazine, tamoxifen, itopride, loxapine, xanomeline, tozasertib, dasatinib, and clozapine were significantly correlated (r = 0.60, p  8.4, could prove useful for predicting the contributions of FMO3 to N-oxygenations as part of drug development. The predicted contributions of FMOs to the N-oxygenation of drug candidates can be simply estimated using classic base dissociation constants.
  • ||||||||||  Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie
    Trial initiation date:  Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders (clinicaltrials.gov) -  Dec 14, 2021   
    P4,  N=78, Recruiting, 
    The predicted contributions of FMOs to the N-oxygenation of drug candidates can be simply estimated using classic base dissociation constants. Initiation date: Aug 2021 --> Jan 2021
  • ||||||||||  Ganaton (itopride) / Abbott
    Journal:  Altered dopamine signalling in chronic epigastric pain syndrome. (Pubmed Central) -  Nov 12, 2021   
    Sulpiride subsided epigastric pain in 73.3%, but itopride reduced it only in 6.6% of CEPS patients. We concluded that altered dopamine signalling may affect locally-and-centrally mediated chronic epigastric pain.
  • ||||||||||  Ganaton (itopride) / Abbott
    Journal:  Gastroesophageal reflux disease - from the point of view of a gastroenterologist, otolaryngologist and surgeon. (Pubmed Central) -  Oct 30, 2021   
    The greatest therapeutic effectiveness is achieved by combining PPI with itopride while maintaining the appropriate doses of drugs and observing a sufficiently long duration of treatment, while maintaining the correct dose reduction and drug discontinuation regimen. In case of failure of pharmacological treatment, antireflux surgery should be take into consideration.
  • ||||||||||  Ganaton (itopride) / Abbott
    Preclinical, Journal:  In vivo drug interactions of itopride and trimethylamine mediated by flavin-containing monooxygenase 3 in humanized-liver mice. (Pubmed Central) -  Oct 22, 2021   
    With the higher dose of trimethylamine, the areas under the concentration-time curves of itopride and its N-oxide significantly increased (1.6-fold) and decreased (to 60%), respectively; modeling suggested that these modified pharmacokinetics resulted from suppression of the in vivo hepatic intrinsic clearance (to 67%). These results suggest that food-derived trimethylamine may result in interactions with FMO drug substrates immediately after administration; however, the potential for this to occur in vivo may be limited.
  • ||||||||||  Ganaton (itopride) / Abbott
    Enrollment open, Trial completion date, Trial primary completion date:  Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy (clinicaltrials.gov) -  Sep 2, 2021   
    P=N/A,  N=525, Enrolling by invitation, 
    These results suggest that food-derived trimethylamine may result in interactions with FMO drug substrates immediately after administration; however, the potential for this to occur in vivo may be limited. Active, not recruiting --> Enrolling by invitation | Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Oct 2021 --> Oct 2022
  • ||||||||||  Ganaton (itopride) / Abbott
    Journal:  Voltammetric determination of itopride using carbon paste electrode modified with Gd doped TiO2 nanotubes. (Pubmed Central) -  Jan 26, 2021   
    Gd doped TNT modified electrode has been used as working electrode for itopride assay in a pharmaceutical formulation. Cyclic voltammetry analysis showed high correlation coefficient of 0.9973 for itopride (0.04-0.2 mg/mL) with a limit of detection (LOD) and limit of quantitation values (LOQ) of 2.9 and 23.0 μg.mL respectively.
  • ||||||||||  Journal:  Risk of domperidone induced severe ventricular arrhythmia. (Pubmed Central) -  Dec 16, 2020   
    Domperidone, mosapride, or itopride use is associated with an increased risk of severe VA. However, the magnitude of association was modest and domperidone use does not increase further the risk, compared with other prokinetics.
  • ||||||||||  Ganaton (itopride) / Abbott
    New trial:  Probiotics and Irritable Bowel Syndrome (clinicaltrials.gov) -  Sep 30, 2020   
    P=N/A,  N=90, Completed, 
  • ||||||||||  Acofide (acotiamide) / Zeria, Astellas, Ganaton (itopride) / Abbott
    Retrospective data, Review, Journal:  Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. (Pubmed Central) -  Sep 17, 2020   
    However, the magnitude of association was modest and domperidone use does not increase further the risk, compared with other prokinetics. TCAs, histamine- receptor antagonists, standard- and low-dose proton pump inhibitors, sulpiride or levosulpiride, itopride and acotiamide were all more efficacious than placebo for FD.
  • ||||||||||  Ganaton (itopride) / Abbott
    Clinical, Journal:  Effect of herb-partitioned moxibustion at fanwei point on plasma motilin and serum gastrin in patients of diabetic gastroparesis (Pubmed Central) -  Jul 30, 2020   
    TCAs, histamine- receptor antagonists, standard- and low-dose proton pump inhibitors, sulpiride or levosulpiride, itopride and acotiamide were all more efficacious than placebo for FD. Herb-partitioned moxibustion at fanwei point relieves the clinical symptoms in the patients with diabetic gastroparesis and increases the gastric emptying rate, which is probably related to the regulation of the levels of plasma motilin and serum gastrin.
  • ||||||||||  Retrospective data, Review, Journal:  Efficacy Comparison of Different Acupuncture Treatments for Functional Dyspepsia: A Systematic Review with Network Meta-Analysis. (Pubmed Central) -  Apr 9, 2020   
    NMA results showed that five types of acupuncture (manual acupuncture, acupoint application, moxibustion, acupoint catgut embedding, and warm acupuncture alone) all were superior to prokinetics (itopride, mosapride, and domperidone) and sham acupuncture in terms of improving the symptoms of functional dyspepsia...It should, therefore, be considered as an alternative treatment for FD patients who are unresponsive to prokinetics or intolerant to the adverse effects of prokinetics. We recommend further multiple centers and high-quality RCT studies to confirm the present findings.
  • ||||||||||  Levobren (levosulpiride) / AbbVie, Imperan (metoclopramide) / Generic Mfg.
    Journal:  Trends in the Prevalence of Drug-Induced Parkinsonism in Korea. (Pubmed Central) -  Sep 27, 2019   
    To prevent or decrease DIP, we suggest that physicians reduce prescriptions of benzamide derivatives that have been most commonly used, and that attempts be made to find other alternative drugs. Additionally, the need for continuing education about offending drugs should be emphasized.